Updating results

6 results for urinary tract infections

Sort: Relevance | Date

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

Evidence summary Published July 2013

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014